Assessment of plasma lactoferrin in Parkinson's disease

Movement Disorders

Volumn 16, Issue 1, 2001, Pages 131-134

  Grau, Armin J ^a   Willig, Vera ^a   Fogel, Wolfgang ^a   Werle, Egon ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Ferritin; Iron; Lactoferrin; Parkinson's disease; Transferrin

Indexed keywords

AMANTADINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; FERRITIN; IRON; LACTOFERRIN; LEVODOPA; MONOAMINE OXIDASE INHIBITOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; DISEASE SEVERITY; FEMALE; FERRITIN BLOOD LEVEL; HUMAN; LONGITUDINAL STUDY; MALE; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; STATISTICAL ANALYSIS; SUBSTANTIA NIGRA;

DOPAMINE; FEMALE; HUMANS; LACTOFERRIN; MALE; MIDDLE AGED; PARKINSON DISEASE; SEVERITY OF ILLNESS INDEX; SUBSTANTIA NIGRA; TRANSFERRIN;

EID: 0035241262     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/1531-8257(200101)16:1<131::AID-MDS1008>3.0.CO;2-O     Document Type: Article

References (13)

1. Fahn S, Cohen G. The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Ann Neurol 1992;32:804-812.
2. Faucheux BA, Nillesse N, Damier Ph, et al. Expression of lactoferrin receptors is increased in the mesencephalon of patients with Parkinson disease. Proc Natl Acad Sci USA 1995;92:9603-9607.
3. Leveugle B, Faucheux BA, Bouras C, et al. Cellular distribution of the iron-binding protein lactotransferrin in the mesencephalon of Parkinson's disease cases. Acta Neuropathol 1996;91:566-572.
4. Fillebeen C, Descamps L, Dehouck MP, et al. Receptor-mediated transcytosis of lactoferrin through the blood-brain barrier. J Biol Chem 1999;274:7011-7017.
5. Bonn D. Pumping iron in Parkinson's disease. Comment. Lancet 1996;347:1614.
6. Aisen P, Leibman A. Lactoferrin and transferrin: a comparative study. Biochim Biophys Acta 1972;257:314-323.
7. Lönnerdal B, Iyer S. Lactoferrin: molecular structure and biological function. Annu Rev Nutr 1995;15:93-110.
8. Lash JA, Coates TD, Lafuze J, Baehner RL, Boxer LA. Plasma lactoferrin reflects granulocyte activation in vivo. Blood 1983;61: 885-888.
9. Logroscino G, Marder K, Graziano J, et al. Altered systemic iron metabolism in Parkinson's disease. Neurology 1997;49:714-717.
10. Abbott RA, Cox M, Markus H, Tomkins A. Diet, body size and micronutrient status in Parkinson's disease. Eur J Clin Nutr 1992; 46:879-884.
11. Cabrera-Valdivia F, Jiménez-Jiménez FJ, Molina JA, et al. Peripheral iron metabolism in patients with Parkinson's disease. J Neurol Sci 1994;125:82-86.
12. Dexter DT, Carayon A, Javoy-Agid F, et al. Alterations in the levels of iron, ferritin, and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain 1991;114:1953-1975.
13. Fillebeen C, Mitchell V, Dexter D, et al. Lactoferrin is synthesized by mouse brain tissue and its expression is enhanced after MPTP treatment. Brain Res Mol Brain Res 1999;72:183-194.